Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 3Radiotherapy, Intensity-Modulated 2Radiation 2pembrolizumab 1palbociclib 1lenvatinib 1gedatolisib 1dabrafenib 1cemiplimab 1atezolizumab 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Platinum 1Neck Dissection 1Everolimus 1Cisplatin 1Atorvastatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × gedatolisib × Head & Neck × Clear all
NCT03065062 2026-02-13

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Suspended
75 enrolled
GastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Neoplasms, Pancreatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡